Melanoma Coverage From Every Angle
Advertisement
Advertisement

Recent News

Is Neoadjuvant Immunotherapy Effective in Treating High-Risk Melanoma?
Enhancing BH3 Mimetic Therapy for Melanoma
Immunotherapy Combination for Metastatic Uveal Melanoma
ESMO 2018: Adjuvant Pembrolizumab and Quality of Life in Patients With High-Risk Melanoma
ESMO 2018: 4-Year Follow-up Confirms Benefit of Nivolumab in Advanced Melanoma
ESMO 2018: Immunotherapy Triplet Therapy for BRAF-Mutated Melanoma
ASTRO 2018: Preclinical Findings on Novel Combination Therapy Against Melanoma
ESMO 2018: Dosing Regimens of Combination Nivolumab and Ipilimumab in Advanced Melanoma
Novel Models for Predicting Skin Cancer Risk
ESMO 2018: Early Results With Novel Monoclonal Antibody in Advanced Melanoma
HLA-Peptidomics May Be Useful in Guiding Immunotherapy in Melanoma
Immunotherapy for CDKN2A-Mutated Metastatic Melanoma
Potential of Adding Vaccine to Other Immunotherapies in Melanoma
Novel Approach to Predicting Response to Immunotherapy in Melanoma
Can Combination Therapy Alter PD-1 Resistance in Metastatic Melanoma?
Early Recognition of Malignant Skin Lesions Through Mobile App
Combination Immunotherapy for Patients With Melanoma Metastases to Brain
Does ATRA Have a Future in Immunotherapy for Melanoma?
Patient Interest in MC1R Genetic Testing to Gauge Melanoma Risk
Are Apps Capable of Accurately Diagnosing Skin Cancer?
AAD 2018: Keys to Early Detection of Nail Melanoma
Delayed Skin Reactions Reported With PD-1 Inhibitors
Does Immunotherapy Improve Survival in Patients With Melanoma Brain Metastases?
Combination of Epacadostat and Pembrolizumab in Unresectable or Metastatic Melanoma
Hike Through Alaska Focuses on Skin Cancer Prevention and Detection
Melanoma Mortality Risk and Nonmelanoma Cancer History: Is There a Connection?
Efficacy Results Support Adjuvant Nivolumab in Stage III or IV Melanoma
sBLA for Adjuvant Pembrolizumab Therapy in Advanced Melanoma Accepted by FDA
Combination Therapy for NRAS-Mutant Melanoma
FDA Approves Combination Treatment for BRAF -Mutant Melanoma
ASCO 2018: Combining Ipilimumab With Novel TLR9 Agonist in Metastatic Melanoma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.